Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human lipoprotein lipase is a protein produced through genetic engineering that mimics the function of naturally occurring human lipoprotein lipase (LPL). LPL is a crucial enzyme in triglyceride metabolism, responsible for the hydrolysis of triglycerides from circulating chylomicrons and very low-density lipoproteins (VLDLs) into free fatty acids and monoacylglycerols. This process is essential for lipid clearance from the bloodstream, lipid utilization, and storage. Deficiency in LPL, often due to genetic mutations, leads to severe hypertriglyceridemia and conditions like lipoprotein lipase deficiency (LPLD), which can cause recurrent pancreatitis and other cardiovascular complications. While the recombinant protein itself is primarily available as a research reagent, therapeutic strategies have focused on restoring LPL activity, most notably through gene therapies that deliver the LPL gene to enable the body to produce functional enzyme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human lipoprotein lipase.